Noom Health's GLP-1 Program Slashes Employer Costs by 80%
Event summary
- Noom Health's SmartRx program reduced GLP-1 medication costs by nearly 80% for its first participating employer, projecting $1.3 million in annual spend versus $6.2 million previously.
- The program, launched in January 2026, bypasses traditional Pharmacy Benefit Managers (PBMs) to connect employers directly with brand-name GLP-1 medications.
- SmartRx is an enhancement to Noom Med, Noom’s clinical obesity care program, integrating behavior change support with GLP-1 therapy.
- An actuarial analysis by Accorded projects a 4.1x ROI over three years for Noom Med members combining behavioral support with GLP-1 therapy.
The big picture
The rapid rise in GLP-1 medication costs has created a significant financial burden for employers, prompting a search for alternative solutions. Noom Health's SmartRx program represents a direct challenge to the traditional PBM model, offering a potentially more cost-effective and integrated approach to managing metabolic health. This move highlights a broader shift towards preventative and holistic healthcare solutions, moving away from reactive, condition-specific programs.
What we're watching
- Adoption Rate
- The success of Noom Health's model hinges on broader employer adoption; the current results represent a single client, and scaling this model across diverse organizations will be crucial.
- PBM Response
- Traditional PBMs will likely react to this disruption, potentially through price adjustments or competitive offerings, which could erode Noom Health's cost advantage.
- Clinical Validation
- While early data is promising, sustained clinical validation of the integrated approach (behavioral support + GLP-1) will be necessary to maintain employer interest and justify the program's cost.
Related topics